The Potential of Liposomal Drug Delivery for the Treatment of Inflammatory Arthritis

Seminars in Arthritis and Rheumatism

Volumn 39, Issue 3, 2009, Pages 182-196

  Vanniasinghe, Anne S ^a   Bender, Veronika ^b   Manolios, Nicholas ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

drug delivery; liposomes; rheumatoid arthritis; targeted delivery

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPICILLIN; ANNAMYCIN; ANTIRHEUMATIC AGENT; CHLOROQUINE; CISPLATIN; CLODRONIC ACID; COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOSTEROID; CYCLOSPORIN; DAUNORUBICIN; DOXORUBICIN; GANCICLOVIR; GLUCOCORTICOID; IMMUNOLIPOSOME; INTERLEUKIN 2; LIPOSOME; LURTOTECAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MURAMYL DIPEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NYSTATIN; PREDNISOLONE; PREDNISOLONE SODIUM PHOSPHATE; RETINOIC ACID; STIBOGLUCONATE SODIUM; UNINDEXED DRUG;

ARTHRITIS; BACTERIAL INFECTION; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; INFORMATION RETRIEVAL; KAPOSI SARCOMA; LEISHMANIASIS; LEUKEMIA; LYMPHOMA; MALARIA; MEDLINE; MESOTHELIOMA; MYCOSIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; RETINITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STOMACH CANCER; SYNOVIUM; SYSTEMIC MYCOSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 70449643633     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.08.004     Document Type: Review

References (159)

1. Bangham A.D., Standish M.M., and Watkins J.C. The diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13 (1965) 238-252
2. Lasic D.D. Novel applications of liposomes. Trends Biotechnol 16 7 (1998) 307-321
3. Banerjee R. Liposomes: applications in medicine. J Biomater Appl 16 3 (2001) 3-21
4. Lian T., and Ho R. Trends and developments in liposome drug delivery systems. J Pharm Sci 90 6 (2001) 667-680
5. Immordino M.L., Dosio F., and Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1 3 (2006) 297-315
6. Storm G., and Crommelin D.J.A. Liposomes: quo vadis?. Pharm Sci Technol Today 1 1 (1998) 19-31
7. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J.S.M., Hazes J.M.W., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146 6 (2007) 406-415
8. Boers M. Glucocorticoids in rheumatoid arthritis: a senescent research agenda on the brink of rejuvenation?. Best Pract Res Clin Rheumatol 18 1 (2004) 21-29
9. Hollander J.L., Brown E.M., Jessar R.A., and Brown C.Y. Comparative effects of use of hydrocortisone as a local anti-arthritic agent. JAMA 147 (1951) 1629-1635
10. Funk M., Schulze B., Guenzi E., Michaelis U., Bohnenkamp H., Eichhorn M., et al. Cationic liposomal preparations for the treatment of rheumatoid arthritis (2007) WO/2007/134819, PCT/EP2007/004467
11. Szoka F., and Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann Rev Biophys Bioeng 9 (1980) 467-508
12. Copeland R.A., Pompliano D.L., and Meek T.D. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5 (2006) 730-739
13. Torchilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 8 (2006) 343-375
14. Berger N., Sachse A., Bender J., Schubert R., and Brandl M. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int J Pharm 223 1-2 (2001) 55-68
15. Jousma H., Talsma H., Spies F., Joosten J.G., Junginger H.E., and Crommelin D.J. Characterization of liposomes. The influence of extrusion of multilamellar vesicles through polycarbonate membranes on particle size, particle size distribution and number of bilayers. Int J Pharm 35 3 (1987) 263-274
16. Sharma A., and Sharma U.S. Liposomes in drug delivery: progress and limitations. Int J Pharm 154 2 (1997) 123-140
17. Lasic D.D., and Papahadjopoulos D. Liposomes revisited. Science 267 5202 (1995) 1275-1276
18. Torchilin V.P. Affinity liposomes in vivo: factors influencing target accumulation. J Mol Recognit 9 5-6 (1996) 335-346
19. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 13 12 (1995) 527-537
20. Lasch J., Weissig V., and Brandl M. Preparation of liposomes. 2nd ed. (2003), Oxford University Press, Oxford
21. Papahadjopoulos D., Allen T., Gabizon A., Mayhew E., Matthay K., Huang S., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proceedings of the National Academy of Sciences 88 24 (1991) 11460-11464
22. Takeuchi H., Yamamoto H., and Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47 1 (2001) 39-54
23. Khaw B.A., Torchilin V.P., Berdichevskii V.R., Barsukov A.A., Klibanov A.L., Smirnov V.N., et al. Enhancing specificity and stability of targeted liposomes by coincorporation of sialoglycoprotein and antibody on liposomes. B Exp Biol Med 95 6 (1983) 776-781
24. Lasic D.D., Martin F.J., Gabizon A., Huang S.K., and Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070 (1991) 187-192
25. Klibanov A.L., Maruyama K., Beckerleg A.M., Torchilin V.P., and Huang L. Amphipathic polyethyleneglycols effectively prolong circulation time in liposomes. FEBS Lett 268 1 (1990) 235-237
26. Blume G., and Cevc G. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta 1029 1 (1990) 91-97
27. Senior J., Delgado C., Fisher D., Tilcock C., and Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta 1062 1 (1991) 77-82
28. Storm G., Belliot S.O., Daeman T., and Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17 1 (1995) 31-48
29. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51 4 (1999) 691-744
30. Harrington K.J., Rowlinson-Busza G., Syrigos K.N., Uster P.S., Vile R.G., and Stewart J.S. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. Clin Cancer Res 6 6 (2000) 2528-2537
31. Torchilin V.P., Trubetskoy V.S., Whiteman K.R., Caliceti P., Ferruti P., and Veronese F.M. New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J Pharm Sci 84 9 (1995) 1049-1053
32. Torchilin V.P., Shtilman M.I., Trubetskoy V.S., Whiteman K., and Milstein A.M. Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim Biophys Acta 1195 1 (1994) 181-184
33. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53 2 (2001) 283-318
34. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 73 2-3 (2001) 137-172
35. Lasic D.D., and Templeton N.S. Liposomes in gene therapy. Adv Drug Deliver Rev 20 2-3 (1996) 221-266
36. Mahato R.I., Takemura S., Akamatsu K., Nishikawa M., Takakura Y., and Hashida M. Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(-lysine). Biochem Pharmacol 53 6 (1997) 887-895
37. Templeton N., Lasic D., Frederik P.M., Strey H.H., Roberts D.D., and Pavlakis G.N. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 15 (1997) 647-652
38. Yotnda P., Chen D.-H., Chiu W., Piedra P.A., Davis A., Templeton N.S., et al. Bilamellar cationic liposomes protect adenovectors from pre-existing humoral immune responses. Mol Ther 5 3 (2002) 233-241
39. Schnyder A., Krahenbuhl S., Torok M., Drewe J., and Huwyler J. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem J 377 Pt. 1 (2004) 61-67
40. Boot E., Koning G., Storm G., Wagenaar-Hilbers J., van Eden W., Everse L., et al. CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis. Arthritis Res Ther 7 3 (2005) R604-R615
41. Duzgunes N., and Nir S. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev 40 1-2 (1999) 3-18
42. Schiffelers R., Storm G., and Bakker-Woudenberg I. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 48 3 (2001) 333-344
43. Peyman G.A., Charles H.C., Liu K.R., Khoobehi B., and Niesman M. Intravitreal liposome-encapsulated drugs: a preliminary human report. Int Ophthalmol 12 (1988) 175-182
44. Swenson C.E., Stewart K.A., Hammett J.L., Fitzsimmons W.E., and Ginsberg R.S. Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin. Antimicrob Agents Chemother 34 (1990) 235-240
45. Fierer J., Hatlen L., Lin J.P., Estrella D., Mihalko P., and Yau-young A. Successful treatment using gentamicin liposomes of Salmonella dublin infections in mice. Antimicrob Agents Chemother 34 (1990) 343-348
46. Bermudez L.E., Yau-Young A., Lin J.P., Cogger J., and Young L.J. Treatment of disseminated Mycobacterium avium complex infection of beige mice with liposome-encapsulated aminoglycosides. J Infect Dis 161 (1990) 1262-1268
47. Fielding R.M., Mukwaya G., and Sandhaus R.A. Clinical and preclinical studies with low-clearance liposomal amikacin (MiKasome (R)) (1998), Springer Verlag, Berlin
48. Fielding R.M., Moon-McDermott L., Lewis R.O., and Horner M.J. Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey. Antimicrob Agents Chemother 43 3 (1999) 503-509
49. Williams A.S., Topley N., Dojcinov S., Richards P.J., and Williams B.D. Amelioration of rat antigen-induced arthritis by liposomally conjugated methotrexate is accompanied by down-regulation of cytokine mRNA expression. Rheumatology 40 4 (2001) 375-383
50. Feldmann M., Brennan F.M., and Maini R.N. Rheumatoid Arthritis. Cell 85 3 (1996) 307-310
51. Tran C.N., Lundy S.K., and Fox D.A. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology 12 3 (2005) 183-189
52. Moreland L.W., and O'Dell J.R. Glucocorticoids and rheumatoid arthritis: back to the future?. Arthritis Rheum 46 10 (2002) 2553-2563
53. Doan T., and Massarotti E. Rheumatoid arthritis: an overview of new and emerging therapies. J Clin Pharmacol 45 7 (2005) 751-762
54. Treadwell B.L., Sever E.D., Savage O., and Copeman W.S. Side-effects of long-term treatment with corticosteroids and corticotrophin. Lancet 23 1 (1964) 1121-1123
55. Bonanomi M.H., Velvart M., Stimpel M., Roos K.M., Fehr K., and Weder H.G. Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis. Rheumatol Int 7 5 (1987) 203-212
56. Yokoyama K., Okamoto H., Watanabe M., Suyama T., and Mizushima Y. Development of a corticosteroid incorporated in lipid microspheres (liposteroid). Drugs Exp Clin Res 11 9 (1985) 611-620
57. Goram A.L., and Richmond P.L. Pegylated liposomal doxorubicin: tolerability and toxicity. Pharmacotherapy 21 6 (2001) 751-763
58. Metselaar J.M., Wauben M.H.M., Boerman O.C., van Lent P.L., and Storm G. Long-circulating liposomes for I.V. targeted delivery of glucocorticoids in arthritis. Cell Mol Biol Lett 7 2 (2002) 291-292
59. Yano H., Hirayama F., Kamada M., Arima H., and Uekama K. Colon-specific delivery of prednisolone-appended alphacyclodextrin conjugate: alleviation of systemic side effect after oral administration. J Control Release 79 1-3 (2002) 103-112
60. Lanao J.M., Briones E., and Colino C.I. Recent advances in delivery systems for anti-HIV1 therapy. J Drug Target 15 1 (2007) 21-36
61. Loftsson T., and Stefansson E. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand 80 2 (2002) 144-150
62. Panzner S., Brauer R., Kinne R., and Rauchhaus U. Liposomal glucocorticoids (2006) WO/2004/047792
63. Metselaar J.M., Wauben M.H., Wagenaar-Hilbers J.P., Boerman O.C., and Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 48 7 (2003) 2059-2066
64. Metselaar J.M., and Storm G. Liposomes in the treatment of inflammatory disorders. Exp Opin 2 3 (2005) 465-476
65. Metselaar J., van den Berg W., Holthuysen A., Wauben M., and Storm G van Lent P. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis 63 4 (2004) 348-353
66. Bird H.A., Ring E.F., Daniel R., and Bacon P.A. Comparison of intra-articular methotrexate with intra-articular triamcinolone hexacetonide by thermography. Curr Med Res Opin 5 (1977) 141-146
67. Wigginton S.M., Chu B.C., Weisman M.H., and Howell S.B. Pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. Arthritis Rheum 23 (1980) 119-122
68. Foong W.C., and Green K.L. Retention and distribution of liposome-entrapped {3H} methotrexate in the therapy of rheumatoid arthritis. Recent Prog Med 5 (1989) 261-262
69. Williams A.S., Camilleri J.P., and Williams B.D. Suppression of adjuvant-induced arthritis by liposomally conjugated methotrexate in the rat. Rheumatology 33 6 (1994) 530-533
70. Jadot G., Vaille A., Maldonado J., and Vanelle P. Clinical pharmacokinetics and delivery of bovine superoxide dismutase. Clin Pharmacokinet 28 1 (1995) 17-25
71. Cruz M.E., Manuela Gaspar M., Barbara M., Martins F., and Corvo M.L. Liposomal superoxide dismutases and their use in the treatment of experimental arthritis. Methods Enzymol 391 (2005) 395-413
72. Martins M.B., Gonçalves A.P., and Cruz M.E. Biochemical characterization of an L-asparaginase bioconjugate. Bioconjugate Chem 7 4 (1996) 430-435
73. Corvo M.L., Boerman O.C., Oyen W.J., Jorge J.C., Cruz M.M., Crommelin D.J., et al. Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. Pharm Res 17 5 (2000) 600-606
74. Corvo M.L., Boerman O.C., Oyen W.J.G., Van Bloois L., Cruz M.E., Crommelin D.J., et al. Intravenous administration of superoxide dismutase entrapped in long circulating liposomes: II. In vivo fate in a rat model of adjuvant arthritis. Biochim Biophys Acta 1419 2 (1999) 325-334
75. Gaspar M.M., Boerman O.C., Laverman P., Corvo M.L., Storm G., and Cruz M.E.M. Enzymosomes with surface-exposed superoxide dismutase: in vivo behaviour and therapeutic activity in a model of adjuvant arthritis. J Control Release 117 2 (2007) 186-195
76. Banchereau J., Pascual V., and Palucka A.K. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20 5 (2004) 539-550
77. Brock J.H. Lactoferrin: a multifunctional immunoregulatory protein?. Immunol Today 16 9 (1995) 417-419
78. Guillen C., McInnes I.B., Vaughan D., Speekenbrink A.B., and Brock J.H. The effects of local administration of lactoferrin on inflammation in murine autoimmune and infectious arthritis. Arthritis Rheum 43 9 (2000) 204-209
79. Trif M., Guillen C., Vaughan D.M., Telfer J.M., Brewer J.M., Roseanu A., et al. Liposomes as possible carriers for lactoferrin in the local treatment of inflammatory diseases. Exp Biol Med 226 6 (2001) 559-564
80. van Rooijen N., and van Kesteren-Hendrikx E. Clodronate liposomes: perspectives in research and therapeutics. J Lipos Res 12 1&2 (2002) 81-94
81. Osterman T., Kippo K., Laurdn L., Hannuniemi R., and Sellman R. Effect of clodronate on established adjuvant arthritis. Rheumatol Int 14 (1994) 139-147
82. Osterman T., Virtamo T., Lauren L., Kippo K., Pasanen I., Hannuniemi R., et al. Slow-release clodronate in prevention of inflammation and bone loss associated with adjuvant arthritis. J Pharmacol Exp Ther 280 2 (1997) 1001-1007
83. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs 42 (1991) 919-944
84. Flora L. Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 22 4 (1979) 340-346
85. Francis M.D., Flora L., and King W.R. The effects of disodium ethane-1-hydroxy-1,1-diphosphonates in adjuvant arthritis in rats. Calcif Tissue Res 9 (1992) 109-121
86. Francis M.D., Hovancik K., and Boyce R.W. NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React XI (1989) 239-252
87. Monkkonen J., Liukkonen J., Taskinen M., Heath T.D., and Urtti A. Studies on liposome formulations for intra-articular delivery of clodronate. J Control Release 35 2-3 (1995) 145-154
88. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 10 (1995) 1478-1487
89. Van Rooijen N., Sanders A., and van den Berg W.B. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods 193 1 (1996) 93-99
90. Teronen O., Heikkila P., Konttinen Y.T., Laitinen M., Salo T., Hanemaaijer R., et al. MMP inhibition and down-regulation by bisphosphonates. Ann NY Acad Sci 878 (1999) 453-465
91. Pennanen N., Lapinjoki S., Urtti A., and Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1-beta. IL-6, and TNF-alpha secretion from RAW264 cells in vitro. Pharm Res 12 (1995) 916-922
92. Kinne R.W., Schmidt-Weber C.B., Hoppe R., Buchner E., Palombo-Kinne E., Nurnberg E., et al. Long term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate containing liposomes. Arthritis Rheum 38 12 (1995) 1777-1790
93. Richards P.J., Williams A.S., Goodfellow R.M., and Williams B.D. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology 38 9 (1999) 818-825
94. Ceponis A., Waris E., Monkkonen J., Laasonen l., Hyttinen M., and Solovieva S.A. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis Rheum 44 8 (2001) 1908-1916
95. Richards P.J., Williams B.D., and Williams A.S. Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology 40 9 (2001) 978-987
96. Gomez-Barrena E., Lindroos L., Ceponis A., Lopez-Franco M., Sanchez-Pernaute J., Monkkonen J., et al. Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis. Clin Exp Rheumatol 24 6 (2006) 622-628
97. Muehleman C., Green J., Williams J.M., Kuettner K.E., Thonar E.J., and Sumner D.R. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 10 3 (2002) 226-233
98. Lehmann H.J., Moruritzen U., Christgau S., Cloos P.A., and Christiansen C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 61 (2002) 530-533
99. Dickinson S.C., Vankemmelbeke M.N., Buttle D.J., Rosenberg K., Heinegard G., and Hollander A.P. Cleavage of cartilage oligomeric matrix protein (thrombospondin-5) by matrix metalloproteinases and a disintergrin and metalloproteinase with thrombospondin motif. Matrix Biol 22 3 (2003) 267-278
100. Hauser N., Paulsson M., Kale A.A., and Di Cesare P.E. Tendon extracellular matrix contains pentameric thrombospondin-4 (TSP-4). FEBS Lett 368 (1995) 307-310
101. Rosenberg K., Olsson H., Morgelin M., and Heinegard D. Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen. J Biol Chem 273 32 (1998) 20397-20403
102. Barrera P., Blom A., Van Lent P., Van Bloois L., Beijnen J.H., Van Rooijen N., et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 43 9 (2000) 1951-1959
103. Bing R.J. Cyclooxygenase-2 inhibitors: is there an association with coronary or renal events?. Curr Atheroscler Rep 5 2 (2003) 114-117
104. Alper A.B.J., Meleg-Smith S., and Krane N.K. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 40 5 (2002) 1086-1090
105. Jain S., Jain N., Bhadra D., Tiwary A.K., and Jain N.K. Transdermal delivery of an analgesic agent using elastic liposomes: preparation, characterization and performance evaluation. Curr Drug Deliv 2 3 (2005) 223-233
106. Kaur K., Jain S., Sapra B., and Tiwary A.K. Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation. Curr Drug Deliv 4 (2007) 276-282
107. Stuart J.M., Cremer M.A., Townes A.S., and Kang A.H. Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med 155 (1982) 1-16
108. Terato K., Hasty K.A., Reife R.A., Cremer M.A., Kang A.H., and Stuart J.M. Induction of arthritis with monoclonal antibodies to collagen. J Immunol 148 7 (1992) 2103-2108
109. Nandakumar K.S., Svensson L., and Holmdahl R. Collagen type II specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol 163 (2003) 1827-1837
110. Benoist C., and Mathis D. A revival of the B cell paradigm for rheumatoid arthritis pathogenesis?. Arthritis Res 2 2 (2000) 90-94
111. Basu D., Horvath S., Matsumoto I., Fremont D.H., and Allen P.M. Molecular basis for recognition of an arthritic peptide and a foreign epitope on distinct MHC molecules by a single TCR. J Immunol 164 (2000) 5788-5796
112. Ji H., Gauguier D., Ohmura K., Gonzalez A., Duchatelle V., Dannoy P., et al. Genetic influences on the end-stage effector phase of arthritis. J Exp Med 194 3 (2001) 321-330
113. Matsumoto I., Staub A., Benoist C., and Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286 5445 (1999) 1732-1735
114. Wipke B.T., Wang Z., Kim J., McCarthy T.J., and Allen P.M. Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat Immunol 3 (2004) 366-372
115. Wipke B.T., Wang Z., Kim J., Nagengast W., Reichert D.E., and Allen P.M. Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes. J Immunol 172 (2002) 7694-7702
116. Wipke B.T., and Allen P.M. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol 167 (2001) 1601-1608
117. Lee D.M., Friend D.S., Gurish M.F., Benoist C., Mathis D., and Breener M.B. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297 5587 (2002) 1689-1692
118. Kindt G.C., Moore S.A., She Z.W., and Wewers M.D. Endotoxin priming of monocytes augments Fc gamma receptor cross-linking-induced TNF-alpha and IL-1 beta release. Am J Physiol 265 2 (1993) L178-L185
119. Kinne R.W., Brauer R., Stuhlmuller B., Palombo-Kinne E., and Burmester G.R. Macrophages in rheumatoid arthritis. Arthritis Res 2 3 (2000) 189-202
120. Solomon S., Rajasekaran N.J., Jeisy-Walder E., Snapper S.B., and Illges H. A crucial role for macrophages in the pathology of K/B×N serum-induced arthritis. Eur J Immunol 35 10 (2005) 3064-3073
121. Yamazaki N., Kojima S., and Yokoyama H. Biomedical nanotechnology for active drug delivery systems by applying sugar-chain molecular functions. Curr Appl Phys 5 (2005) 112-117
122. Hirai M., Minematsu H., Kondo N., Oie K., Igarashi K., and Yamazaki N. Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. Biochem Biophys Res Commun 353 3 (2007) 553-558
123. Koning G., Schiffelers R., Wauben M., Kok R., Mastrobattista E., Molema G., et al. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethansone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum 54 4 (2006) 1198-1208
124. Andreev O.A., Dupuy A.D., Segala M., Sandugu S., Serra D.A., Chichester C.O., et al. Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proceedings of the National Academy of Sciences 104 19 (2007) 7893-7898
125. Stubbs M., McSheehy P.M.J., Griffiths J.R., and Bashford C.L. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 6 1 (2000) 15-19
126. Reshetnyak Y.K., Andreev O.A., Lehnert U., and Engelman D.M. Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix. Proceedings of the National Academy of Sciences 103 17 (2006) 6460-6465
127. Ford K., Souberbielle B., Darling D., and Farzaneh F. Protein transduction: an alternative to genetic intervention?. Gene Ther 8 1 (2001) 1-4
128. Liu M., Guo Y., Yang J., Wang P., Zhao L., Shen N., et al. Application of cell penetrating peptide in magnetic resonance imaging of bone marrow mesenchymal stem cells. Acta Biochem Biophys Sin 38 12 (2006) 865-873
129. Noguchi H., and Matsumoto S. Protein transduction technology: a novel therapeutic perspective. Acta Med Okayama 60 1 (2006) 1-11
130. Marty C., Meylan C., Schott H., Ballmer-Hofer K., and Schwendener R. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell Mol Life Sci 61 14 (2004) 1785-1794
131. Green M., and Loewenstein P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus TAT trans-activator protein. Cell 55 6 (1988) 1179-1188
132. Frankel A.D., and Pabo C.O. Cellular uptake of the TAT protein from human immunodeficiency virus. Cell 55 6 (1988) 1189-1193
133. Vives E., Brodin P., and Lebleu B. A truncated HIV-1 TAT protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272 20 (1997) 16010-16017
134. Iwasa A., Akita H., Khalil I., Kogure K., Futaki S., and Harashima H. Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature. Biochim Biophys Acta 1758 6 (2006) 713-720
135. Mi Z., Lu X., Mai J.C., Ng B.G., Wang G., Lechman E.R., et al. Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium. Mol Ther 8 2 (2003) 295-305
136. Torchilin V.P., Rammohan R., Weissig V., and Levchenko T.S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proceedings of the National Academy of Sciences 98 (2001) 8786-8791
137. Gupta B., Levchenko T.S., and Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 57 4 (2005) 637-651
138. Schwarze S., Ho A., Vocero-Akbani A., and Dowdy S. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
139. Harigai T., Hagiwara H., Ogawa Y., Ishizuka T., Kaneda S., and Kimura J. Prednisolone phosphate-containing TRX-20 liposomes inhibit cytokine and chemokine production in human fibroblast-like synovial cells: a novel approach to rheumatoid arthritis therapy. J Pharm Pharmacol 59 1 (2007) 137-143
140. Garrod T., and Pitzalis C. Targeting the inflamed synovium: the quest for specificity. Arthritis Rheum 54 4 (2006) 1055-1060
141. Lee L., Buckley C., Blades M.C., Panayi G., George A.J., and Pitzalis C. Identification of synovium-specific homing peptides by in vivo phage display selection. Arthritis Rheum 46 8 (2002) 2109-2120
142. George A.J.T., Lee L., and Pitzalis C. Isolating ligands specific for human vasculature using in vivo phage selection. Trends Biotechnol 21 5 (2003) 199-203
143. Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M.R., Viale G., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2 11 (1996) 1843-1849
144. Lau D.H., Xue L., Young L.J., Burke P.A., and Cheung A.T. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 14 1 (1999) 31-36
145. Kunstfeld R., Wickenhauser G., Michaelis U., Teifel M., Umek W., Naujoks K., et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. Soc Invest Dermatol 120 3 (2003) 476-482
146. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 351 17 (2004) 1772-1777
147. Taylor P.C., Williams R.O., and Maini R.N. Immunotherapy for rheumatoid arthritis. Curr Opin Immunol 13 5 (2001) 611-616
148. Khoury M., Louis-Plence P., Escriou V., Noel D., Largeau C., Cantos C., et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 54 6 (2006) 1867-1877
149. Morishita R., Kaneda Y., and Ogihara T. Therapeutic potential of oligonucleotide-based therapy in cardiovascular disease. BioDrugs 16 6 (2003) 383-389
150. Dass C.R. Liposome-mediated delivery of oligodeoxynucleotides in vivo. Drug Deliv 9 3 (2002) 169-180
151. Bennett C.F., Chiang M.-Y., Chan H., Shomaker J.E., and Mirabelli C.K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41 6 (1992) 1023-1033
152. Capaccioli G., Di Pasquale G., Mini E., Mazzei T., and Quattrone A. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun 197 2 (1993) 818-825
153. Zelphati O., and Szoka Jr. F.C. Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet?. J Control Release 41 1 (1996) 99-119
154. Tomita T., Takeuchi E., Tomita N., Morishita R., Kaneko M., Yamamoto K., et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of NF-kB decoy oligodeoxynucleotide as gene therapy. Arthritis Rheum 42 (1999) 2532-2538
155. Watson-Clark R.A., Banquerigo M., Shelly K., and Frederick Hawthorne M. Model studies directed toward the application of boron neutron capture therapy to rheumatoid arthritis: boron delivery by liposomes in rat collagen-induced arthritis. Proceedings of the National Academy of Sciences 95 5 (1998) 2531-2534
156. Cullis P.R., Hope M.J., Bally M.B., Madden T.D., Mayer L.D., and Fenske D.B. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331 2 (1997) 187-211
157. Haran G., Cohen R., Bar L.K., and Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151 2 (1993) 201-215
158. Clerc S., and Barenholz Y. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Biochim Biophys Acta 1240 2 (1995) 257-265
159. Grit M., Zuidam N.J., and Crommelin D.J. Analysis and hydrolysis kinetics of phospholipids in aqueous liposome dispersions. In: Gregoriadis G. (Ed). Liposome technology (1996), CRC Press, Boca Raton (FL) 455-486